New application of 13-methylberberine as USP22 inhibitor

By inhibiting USP22 activity, combined treatment with 13-methyl berberine and erlotinib, the problem of lung cancer resistance to EGFR-TKIs was solved, and the sensitivity and therapeutic effect of lung cancer cells were significantly improved.

CN118986978APending Publication Date: 2024-11-22HARBIN MEDICAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410945615.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-15
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The problem of drug resistance of lung cancer to EGFR-TKIs, especially the resistance of erlotinib, leads to reduced therapeutic effects, and new targeted therapeutic strategies need to be explored.

Method used

By inhibiting the deubiquitinase USP22 in the ubiquitin-proteasome pathway, 13-methyl berberine was used to significantly inhibit the activity of USP22, enhancing the sensitivity of lung cancer cells to EGFR-TKIs, and combined with erlotinib. Use to enhance the therapeutic effect.

Benefits of technology

13-methyl berberine significantly inhibits the proliferation, migration and invasion ability of lung cancer cells, promotes apoptosis, and enhances the drug sensitivity of EGFR-TKIs, providing new lung cancer treatment options and significantly improving the therapeutic effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118986978A_ABST
    Figure CN118986978A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of medicines, and particularly relates to novel application of 13-methylberberine and a pharmaceutical composition. The 13-methylberberine has a structure shown in the specification, and can significantly inhibit the expression of USP22 in lung cancer cells, significantly inhibit the proliferation, clone formation ability, invasion and migration ability of the lung cancer cells, and promote the apoptosis of the lung cancer cells. Therefore, the 13-methyl berberine can be used for preparing the medicine for preventing and / or treating the lung cancer. Secondly, the 13-methylberberine can also enhance the drug sensitivity of EGFR-TKIs erlotinib, and the 13-methylberberine and the erlotinib are combined for use, so that a strong synergistic interaction effect is achieved in the aspect of treating the lung cancer, and more treatment choices are provided for clinically treating the lung cancer. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of medical technology, and specifically relates to a new use of 13-methylberberine and a pharmaceutical composition. Background Art

[0002] Lung cancer is a common malignant tumor in my country, with high morbidity and mortality. Due to the low rate of early diagnosis, most lung cancer patients have already developed distant metastasis when diagnosed, with a 5-year overall survival rate of less than 20%, and a poor prognosis. At present, the treatments for lung cancer include surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy. Among them, with the launch of epidermal growth factor receptor Tyrosine kinase inhibitors (EGFR-TKIs), targeted therapy for lung cancer has made breakthroughs and progress. However, recurrence and drug resistance are also one of the important reasons why lung cancer is difficult to cure. How to enhance the efficacy of EGFR-TKIs has always been a difficult problem faced by clinical workers.

[0003] Erlotinib is a first-generation tyrosine kinase inhibitor that selectively binds to the ATP binding site of the epidermal growth factor receptor tyrosine kinase, thereby inhibiting the phosphorylation of the epidermal growth factor receptor and preventing the activation of downstream signaling pathways. Erlotinib was initially approved for advanced non-small cell lung cancer that has failed traditional chemotherapy. Although erlotinib treatment has shown good efficacy, studies have found that almost all tumors will eventually develop resistance to erlotinib through different mechanisms.

[0004] Therefore, it is of great clinical significance to study the mechanism of lung cancer progression and identify valuable prognostic markers and therapeutic targets as well as develop new targeted drugs.

[0005] The ubiquitin-proteasome pathway is one of the main pathways for intracellular protein degradation, and regulates the homeostasis of intracellular proteins through ubiquitination and proteasome degradation. Some studies have found that abnormal activation of the ubiquitin-proteasome pathway in tumor cells is closely related to the occurrence and deterioration of tumors. Deubiquitinating enzymes play a vital role in regulating the ubiquitination process and have an important impact on the occurrence and development of tumors. Ubiquitin-specific protease 22 (USP22) is an important deubiquitinating enzyme. USP22 plays an important role in regulating biological processes such as cell cycle, DNA repair, and transcriptional regulation. USP22 is highly expressed in a variety of tumors and is closely related to the occurrence, development, and treatment resistance of tumors. Therefore, researchers are committed to exploring the mechanism of action of USP22 in tumors and developing anti-tumor treatment strategies for USP22. The inventors found through research that USP22 is highly expressed in lung cancer patient tissues and is associated with poor prognosis in lung cancer patients. Therefore, USP22 may be a potential therapeutic target for lung cancer. On this basis, the inventors further discovered that the compound 13-methylberberine (2,3-methylenedioxy-10,11-dimethoxy-13-methylprotoberberine chloride, 13-MB) can effectively inhibit the activity of USP22 to exert anti-tumor effects, and can enhance the drug sensitivity of lung cancer to EGFR-TKIs to exert anti-tumor effects, and thus can be used to prepare anti-tumor drugs. Summary of the invention

[0006] The purpose of the present invention is to provide a new use of 13-methylberberine and a pharmaceutical composition, wherein the 13-methylberberine can significantly inhibit the expression of USP22 in lung cancer cells, significantly inhibit the proliferation, cloning ability, invasion and migration ability of lung cancer cells, and promote the apoptosis of lung cancer cells. In addition, the 13-methylberberine can also enhance the drug sensitivity of EGFR-TKIs erlotinib, and the combination of 13-methylberberine and erlotinib has a synergistic effect in the treatment of lung cancer.

[0007] Specifically, the present invention is realized through the following technical solutions:

[0008] In a first aspect, the present invention provides a use of 13-methylberberine in the preparation of a drug for preventing and / or treating lung cancer, wherein the molecular formula of the 13-methylberberine is C 21 H 20 ClNO4, the chemical structure is as follows:

[0009]

[0010] In one embodiment, in the above use, the 13-methylberberine prevents and / or treats lung cancer by inhibiting the expression of USP22.

[0011] In one embodiment, in the above use, the 13-methylberberine prevents and / or treats lung cancer by inhibiting the proliferation, invasion and migration ability of lung cancer cells and promoting apoptosis of lung cancer cells.

[0012] In one embodiment, in the above use, the 13-methylberberine can be prepared into an oral preparation with a pharmaceutically acceptable carrier or excipient.

[0013] In one embodiment, the oral formulation is a tablet, capsule, granule or oral solution.

[0014] In a second aspect, the present invention provides a use of the above-mentioned 13-methylberberine in the preparation of a USP22 inhibitor.

[0015] In a third aspect, the present invention provides a use of the above-mentioned 13-methylberberine in the preparation of a drug for inhibiting or knocking out USP22.

[0016] In a fourth aspect, the present invention provides a pharmaceutical composition for preventing and / or treating lung cancer, the pharmaceutical composition comprising EGFR-TKIs erlotinib and 13-methylberberine, wherein the molar ratio of erlotinib to 13-methylberberine is 0.3-6:1.

[0017] In one embodiment, in the above pharmaceutical composition, the molar ratio of the erlotinib to the 13-methylberberine is 0.5-4:1, preferably 2:1.

[0018] In a fifth aspect, the present invention provides a use of the pharmaceutical composition described in the second aspect above in the preparation of a drug for preventing and / or treating lung cancer.

[0019] In one embodiment, in the above use, the erlotinib and the 13-methylberberine can be prepared into an oral preparation with a pharmaceutically acceptable carrier or excipient.

[0020] In one embodiment, the oral formulation is a tablet, capsule, granule or oral solution.

[0021] As used herein, the "pharmaceutically acceptable carrier or excipient" of the present invention refers to a conventional drug carrier in the field of pharmaceutical preparations, selected from one or more of fillers, binders, lubricants, suspending agents, disintegrants, wetting agents, flavoring agents, pigments, solvents, and surfactants.

[0022] The filler of the present invention includes but is not limited to starch, sucrose, dextrin, microcrystalline cellulose, lactose, glucose, etc.; the binder includes but is not limited to water, ethanol, syrup, starch slurry, sodium carboxymethyl cellulose, sodium alginate, polyvinyl pyrrolidone, etc.; the lubricant includes but is not limited to stearic acid, sodium chloride, sodium oleate, sodium lauryl sulfate, poloxamer, etc.; the suspending agent includes but is not limited to polysaccharides such as acacia gum, agar, alginic acid, cellulose ether and carboxymethyl chitosan, etc.; the disintegrant includes but is not limited to starch effervescent mixture, i.e. sodium bicarbonate and citric acid, tartaric acid, low-substituted hydroxypropyl cellulose, etc.; the solvent includes but is not limited to water, a balanced salt solution, etc.

[0023] The above-mentioned various dosage forms can be prepared according to conventional processes in the field of pharmaceutical preparations.

[0024] As used herein, 13-methylberberine and erlotinib of the present invention were purchased from commercially available products.

[0025] In the medical uses described above, the administration time, number of administrations and frequency of administration of various active ingredients need to be determined according to the specific diagnosis results of the disease, which is within the technical scope mastered by those skilled in the art.

[0026] Compared with the prior art, the present invention has the following beneficial effects:

[0027] (1) The present invention provides a new use of 13-methylberberine, which can significantly inhibit the expression of USP22 in lung cancer cells, significantly inhibit the proliferation, cloning ability, invasion and migration ability of lung cancer cells, and promote the apoptosis of lung cancer cells. Therefore, the 13-methylberberine can be used to prepare a drug for preventing and / or treating lung cancer.

[0028] (2) The 13-methylberberine provided by the present invention can also enhance the drug sensitivity of EGFR-TKIs erlotinib. The combination of 13-methylberberine and erlotinib has a strong synergistic effect in the treatment of lung cancer, providing more treatment options for the clinical treatment of lung cancer. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] The accompanying drawings are used to provide a further understanding of the present invention and constitute a part of the specification. Together with the embodiments of the present invention, they are used to explain the present invention and do not constitute a limitation of the present invention. In the accompanying drawings, "*" represents P<0.05, and there is statistical significance between the groups:

[0030] Figure 1 Shows the expression of USP22 in lung cancer tissues and lung cancer cell lines with EGFR mutations. Figure 1A: GEO database analysis of USP22 expression levels in lung cancer tumor tissues and normal tissues; B: USP22 knockdown cell model was constructed in the EGFR-TKIs-resistant cell line H1975, and gene chip analysis was performed; C: IPA analysis; D: Pathway enrichment analysis; E: Western blot experiment to detect the expression of USP22 in EGFR-TKIs-resistant cell lines (H1975 and H1650) and EGFR-TKIs-sensitive cell lines (PC9 and HCC827); F: USP22 knockdown and overexpression cell lines were constructed and verified by Western blot and qRT-PCR experiments.

[0031] Figure 2 It shows that USP22 can promote the proliferation of lung cancer cells and inhibit the apoptosis of lung cancer cells. Figure 2 In the figure, A: EdU cell proliferation assay was used to detect the effect of USP22 on the proliferation ability of lung cancer cells; B: clone formation assay was used to detect the effect of USP22 on the clone formation ability of lung cancer cells; C: flow cytometry was used to detect the regulation of USP22 on the cell cycle of lung cancer; D: flow cytometry was used to detect the effect of USP22 on the apoptosis ability of lung cancer cells.

[0032] Figure 3 It was shown that USP22 promoted the migration and invasion of lung cancer cells and attenuated the sensitivity of lung cancer cells to the EGFR-TKIs erlotinib. Figure 3 A: Transwell assay to detect the effect of USP22 on the migration and invasion of lung cancer cells; B: Cell scratch assay to detect the effect of USP22 on the migration of lung cancer cells; C: CCK-8 assay to detect the effect of USP22 on the sensitivity of lung cancer cells to EGFR-TKIs erlotinib.

[0033] Figure 4 It was shown that USP22 stabilizes EGFR expression through deubiquitination. Figure 4 In the figure, A: Immunofluorescence experiment explored the relationship between USP22 and the cell endocytosis pathway; B: Western blot and qRT-PCR verified the regulatory effect of USP22 on EGFR; C: Western blot verified that USP22 prolonged the half-life of EGFR; D: Western blot experiment verified that USP22 reduced the ubiquitination level of EGFR; E: Western blot experiment verified that the proteasome inhibitor MG132 can stabilize the protein expression level of EGFR.

[0034] Figure 5 USP22 was shown to reduce erlotinib-mediated antitumor activity. Figure 5 In the figure, A: mouse tumor size; B: mouse tumor weight statistics; C: mouse tumor tissue immunohistochemical staining results.

[0035] Figure 6 It showed that 13-MB could inhibit the protein expression level of USP22. Western blot experiment detected the expression of USP22 in lung cancer cells after treatment with different concentrations of 13-MB.

[0036] Figure 7 It was shown that 13-MB could inhibit the proliferation, migration and invasion of lung cancer cells and promote apoptosis of lung cancer cells. Figure 7 A: CCK-8 assay was used to detect the proliferation of lung cancer cells after treatment with 13-MB at different concentrations and for different time periods; B: 13-MB could inhibit the cloning ability of lung cancer cells; C: EdU cell proliferation assay was used to detect the proliferation of lung cancer cells after treatment with different doses of 13-MB; D: Transwell assay was used to observe the migration and invasion of lung cancer cells after treatment with 0μM, 20μM, and 40μM 13-MB; E: Flow cytometry was used to detect the apoptosis of lung cancer cells after treatment with 0μM, 20μM, and 40μM 13-MB.

[0037] Figure 8 It was shown that 13-MB could enhance the anti-tumor activity mediated by erlotinib. Figure 8 A, B: CCK-8 method to detect the drug sensitivity of H1975 to erlotinib; C: mouse tumor size at the end point of the transplanted tumor model experiment; D: mouse tumor volume change curve. DETAILED DESCRIPTION

[0038] The embodiments of the present invention are described in detail below. The embodiments are given to better illustrate the contents of the present invention and are only used to explain the present invention, but should not be understood as limiting the present invention.

[0039] If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased through regular channels.

[0040] The experimental methods in the following examples are conventional methods unless otherwise specified. The experimental materials used in the following examples are commercially available products unless otherwise specified.

[0041] Example 1

[0042] Pharmacodynamics experiments

[0043] 1. Experimental Methods

[0044] 1.1 Cell proliferation experiment: CCK-8 method: Lung cancer cells were inoculated in 96-well plates, and different concentrations (0μM, 10μM, 20μM, 40μM, 80μM) of 13-MB were used to treat the cells. After culturing for 24, 48, and 72 hours, 10μl CCK-8 reagent was added to each well, incubated at 37°C for 2 hours, and the absorbance at 450nm was measured to evaluate the proliferation ability of the cells. EdU cell proliferation experiment: Lung cancer cells were inoculated in 96-well plates, and EdU fluorescent markers were added to the cell culture medium after the cells adhered to the wall, incubated at 37°C for 4 hours, and fixed with 4% paraformaldehyde for 20 minutes. The fixed cells were permeabilized for 10 minutes to allow the fluorescent markers to penetrate the cell membrane. Use the EdU detection kit according to the instructions for the next operation. Finally, the fluorescence signal of the cells was observed using a fluorescence microscope to determine the uptake of EdU in the cells and then judge the proliferation activity of the cells.

[0045] 1.2 Clone formation experiment: Add 2 ml of complete culture medium containing 800-1000 lung cancer cells to each well of a six-well plate. Observe the clone formation regularly and culture in a six-well plate for 2 weeks. After the clone is formed, discard the culture medium, add PBS to wash, discard the PBS, fix with 4% paraformaldehyde for 20 minutes, add crystal violet for staining, wash, dry, take pictures, and count after staining. According to the number and morphology of clones formed, evaluate and compare the proliferation ability and clone formation ability of the cells.

[0046] 1.3 Transwell experiment: Prepare a 24-well plate, add 500 μl of complete culture medium to each well, and then put it into the Transwell chamber. The chamber for the invasion experiment contains matrix gel, and the chamber for the migration experiment does not contain matrix gel. According to the migration and invasion characteristics of different cells, serum-free culture medium is used to culture at 37°C for several hours to several days. After the culture is completed, the chamber is removed, the culture medium is discarded, washed with PBS, fixed with methanol for 20 minutes, and stained with crystal violet for 20 minutes. After the staining is completed, the upper cells of the chamber are scraped off with a cotton swab, cleaned, dried at room temperature, photographed, and counted. The migration and invasion ability of cells is evaluated by analyzing the number and morphological characteristics of migrating or invading cells.

[0047] 1.4 Cell apoptosis experiment: Collect all the supernatant of lung cancer cells, collect cells with trypsin digestion solution without EDTA, wash cells with PBS, centrifuge at 2000rpm for 5 minutes at room temperature. Resuspend cells with 500μl 1×Annexin Buffer, add 5μl Annexin V-FITC and mix well, add 5μl Propidium Iodide and mix well, react at room temperature, avoid light, react for 5-15 minutes, and perform flow cytometry detection and data analysis within 1 hour.

[0048] 1.5 Cell cycle detection: Digest lung cancer cells with trypsin and collect them into a centrifuge tube, centrifuge at 1000x g for 5 minutes, and discard the supernatant; add 1ml pre-cooled PBS to resuspend the cells and transfer them to a 1.5ml centrifuge tube, centrifuge again to precipitate the cells, and discard the supernatant; resuspend the cells in 250μl pre-cooled PBS, slowly add 750μl pre-cooled anhydrous ethanol and mix; place the sample at -20℃, fix overnight, centrifuge at 1000×g for 5 minutes, and discard the supernatant; add about 1mL of ice-cold PBS, resuspend the cells, centrifuge at 1000×g for 5 minutes, and discard the supernatant. Add RNase A to the cell pellet, mix well and incubate at 37℃ for 30 minutes, add 500μl propidium iodide staining solution to the sample, mix well and incubate at room temperature in the dark for 30 minutes, and perform flow cytometry detection.

[0049] 1.6 Tumor-bearing experiment in nude mice: The Balb / c nude mice used in this experiment were 4-6 weeks old female mice. H1975 lung cancer cells (5×10 6 cells) were made into a 100 μl suspension and injected into the back of nude mice to complete the nude mouse tumor-bearing experiment. After the tumor was formed, the weight of the mice and the size of the tumor were measured regularly. The volume of the tumor was calculated as: length × width × width × 0.5. When the tumor volume reached the appropriate size, the nude mice were killed and the tumor was peeled off, weighed, and photographed. Some tumors were fixed with paraformaldehyde and embedded in paraffin, and the rest were stored in liquid nitrogen for RNA and protein extraction.

[0050] 1.7 Western blot: Collect lung cancer cells, use RIPA lysis buffer and add protease inhibitors and phosphatase inhibitors, centrifuge at 4℃12000rpm for 30 minutes to obtain protein supernatant, and detect protein concentration by BCA method. The protein sample is separated by SDS-PAGE electrophoresis and transferred to the membrane, and then the PVDF membrane is blocked and incubated with antibodies. Finally, by adding color substrate, the expression of protein is observed under optical conditions. Through the above steps, the expression level of the target protein in the sample can be detected, and semi-quantitative or quantitative analysis can be performed.

[0051] 1.8 Immunofluorescence: First, fix the cells with paraformaldehyde, permeabilize with 0.1% Triton-100 for 10 minutes, and wash with PBS three times, 5 minutes each time. Then use 4% BSA for blocking steps to reduce nonspecific binding. Drop the primary antibody containing the target protein antibody on the sample and incubate it at 4°C overnight. On the second day, wash away the primary antibody with PBS and incubate with the secondary antibody, incubate at room temperature for 1 hour, and use DAPI staining solution to stain the nucleus. Finally, place the slide under a fluorescence microscope to observe and analyze the distribution of the target protein.

[0052] 1.9 Immunohistochemistry: Immunohistochemistry was used to detect the expression of USP22 in lung cancer. Tissue samples were fixed on glass slides and dehydrated and dewaxed to maintain the structural integrity of the samples. Antibodies were used to detect specific antigenic proteins. The target protein was labeled by adding a dye to make it visible under a microscope. The stained samples were observed under a microscope to determine the presence and distribution of the target protein. Immunohistochemistry staining was scored according to the following criteria: "-" indicates no positively stained cells, "+" indicates 1-20% positive cells, "++" indicates 20-50% positive cells, and "+++" indicates 50-100% positive cells. IHC expression of the protein was evaluated: "-~+" was defined as low expression; "++~+++" was defined as high expression.

[0053] 1.10 Co-immunoprecipitation experiment (Co-IP): Add appropriate amount of cell IP lysis buffer, lyse for 30 minutes, and take the supernatant after centrifugation: add 1μg of corresponding antibody and 50μl proteinA / G-beads to the cell lysate overnight; after immunoprecipitation reaction, centrifuge for 5 minutes, remove the supernatant, and then perform Western blot analysis.

[0054] 2. Experimental results

[0055] 2.1 Expression of USP22 in lung cancer tissues and EGFR mutant lung cancer cell lines. Figure 1 As shown in Figure A, in order to analyze the expression of USP22 in lung cancer and normal tissues, we used the GEO public dataset (GSE18842) through bioinformatics analysis and found that compared with normal lung tissue, the mRNA expression level of USP22 in lung adenocarcinoma tissue was significantly increased (P<0.05).

[0056] In order to further explore the role of USP22 in lung cancer, we selected lung cancer H1975 cells to construct a USP22 knockdown cell line and used gene chip technology for sequencing analysis. Figure 1 As shown in Figure B, through bioinformatics analysis of differentially expressed genes (the screening criteria for significantly differentially expressed genes must meet the requirements of Fold change>4 and P-value<0.001), there are 2171 differentially expressed genes, including 1087 up-regulated genes and 1084 down-regulated genes. Figure 1 As shown in Figure C, IPA analysis revealed that USP22 affects many biological functions of lung cancer cells, such as cell homeostasis, apoptosis, lung cancer formation, etc. Figure 1As shown in Figure D, enrichment analysis of differentially expressed genes in classical signaling pathways revealed that USP22 affects many classical signaling pathways related to lung adenocarcinoma, including the EMT signaling pathway, the mTOR signaling pathway, the clathrin-mediated endocytosis pathway, and so on. Next, we explored whether USP22 would regulate the drug resistance of EGFR mutant lung cancer to EGFR-TKIs. Figure 1 As shown in Figure E, Western blot experiments revealed that the protein expression level of USP22 in EGFR-TKIs-resistant cell lines H1975 and H1650 was significantly higher than that in EGFR-TKIs-sensitive cell lines PC9 and HCC827. Figure 1 As shown in Figure F, we used lentivirus to construct USP22 knockdown (H1975 cells) and overexpression (PC9 cells) cell lines, and verified the above USP22 expression results by Western blot and qRT-PCR experiments.

[0057] 2.2 USP22 promotes the proliferation of lung cancer cells and inhibits the apoptosis of lung cancer cells. In order to explore whether USP22 can affect the proliferation ability of EGFR mutant lung cancer cells, we performed EdU experiments to detect cell proliferation ability. Figure 2 As shown in Figure A, the EdU experiment found that compared with the control group, knocking down USP22 significantly inhibited the growth and proliferation of the EGFR-TKIs-resistant cell line H1975 cells, while overexpressing USP22 promoted the growth and proliferation of the EGFR-TKIs-sensitive cell line PC9 cells. Figure 2 As shown in Figure B, USP22 enhanced the cloning ability of tumor cells through cell cloning experiments. Next, we performed cell cycle and cell apoptosis detection using flow cytometry. Figure 2 As shown in Figure C, flow cytometry technology revealed that compared with the control group, after knocking down USP22, the number of H1975 cells in the G1 phase increased significantly (knockdown vs control: 71% vs 54%), and the number of cells in the G2 / S phase decreased (knockdown vs control: 29% vs 46%); compared with the control group, after overexpressing USP22, the number of EGFR-TKIs sensitive cell line PC9 cells in the G1 phase decreased significantly (overexpression vs control: 69% vs. 79%), and the number of cells in the G2 / S phase increased (knockdown vs control: 31% vs 21%). Figure 2 As shown in Figure D, cell apoptosis analysis showed that compared with the control group, the apoptosis rate of H1975 cells increased after knocking down USP22 (knockdown vs control: 5.2% vs 2.8%); compared with the control group, overexpression of USP22 significantly inhibited the apoptosis of PC9 cells (overexpression vs control: 0.7667% vs. 2.267%).

[0058] 2.3 USP22 promotes cell migration and invasion and reduces the sensitivity of lung cancer cells to EGFR-TKIs. We further investigated the potential effects of USP22 on the migration and invasion of lung cancer cells. Figure 3 As shown in A and B, the Transwell experiment found that after knocking out USP22, the migration and invasion ability of EGFR-TKIs resistant cell line H1975 cells were significantly inhibited; after overexpressing USP22, the migration and invasion ability of EGFR-TKIs sensitive cell line PC9 cells were significantly enhanced. Next, we evaluated the role of USP22 in affecting the sensitivity of EGFR mutant lung cancer cells to EGFR-TKIs drugs in vitro. The present invention uses erlotinib for research, Figure 3 As shown in Figure C, the CCK8 method revealed that after knocking down USP22, the sensitivity of H1975 cells to erlotinib increased; after overexpressing USP22, the sensitivity of PC9 cells to erlotinib decreased.

[0059] 2.4 USP22 regulates the ubiquitination level of EGFR. EGFR is located on the surface of epithelial cells and can regulate the expression of EGFR through endocytosis and deubiquitination. Therefore, we first determined the subcellular localization of USP22 in H1975 cells and PC9 cells by immunofluorescence experiments to explore its role in the endocytic pathway. Figure 4 As shown in Figure A, we found through immunofluorescence experiments that USP22 co-localizes with the late endosomal marker Rab7, indicating that USP22 is directly involved in endocytosis. Figure 4 As shown in Figure B, after knocking down USP22 in 1975 cells and overexpressing USP22 in PC9 cells, Western blot and qRT-PCR experiments verified that USP22 did not affect the mRNA level of EGFR, but affected the protein level of EGFR. Figure 4 As shown in Figure C, Western blot experiments revealed that the half-life of EGFR in H1975 cells was significantly shortened after knocking down USP22 when the EGF (100 ng / mL) treatment time was 0-180 minutes, regardless of whether the protein synthesis inhibitor - cycloheximide (CHX) (200 ug / mL, action time 6 hours) was used; the half-life of EGFR in PC9 cells was significantly increased after overexpressing USP22. After stimulating H1975 and PC9 cells with EGF (100 ng / mL) for 15 minutes, we collected the cells and extracted proteins for immunoprecipitation experiments. Figure 4As shown in Figure D, through co-IP experiments, it was found that knocking out USP22 would increase the ubiquitination level of EGFR; overexpression of USP22 reduced the ubiquitination level of EGFR. Next, we further treated the cells with the proteasome inhibitor MG132 at a concentration of 20 μM for 2 hours, collected the cells, and extracted the proteins. Figure 4 As shown in Figure E, Western blot experiments revealed that MG132 can protect EGFR from degradation in H1975 cells. The above results indicate that USP22 inhibits the ubiquitination level of EGFR through deubiquitination modification and stabilizes the protein expression of EGFR.

[0060] 2.5 USP22 weakened the anti-lung cancer activity mediated by erlotinib. Balb / c Nude mice, 4-6 weeks old female mice, were used for the experiment. USP22 control and knockdown H1975 lung cancer cells (5×10 6 cells) were made into a 100 μl suspension and injected into the back of nude mice. One week later, the mice were given erlotinib (25 mg / kg) orally, and the control group was given sterile water orally once a day. The weight of the mice and the size of the tumor were measured regularly, and the volume of the tumor was calculated as: length × width × width × 0.5. After 3 weeks, the nude mice were killed, the tumors were peeled off, weighed, and photographed. Some tumors were fixed with paraformaldehyde and embedded in paraffin, and the rest were stored in liquid nitrogen and can be used for RNA and protein extraction. Figure 5 It can be seen that compared with the control group, the tumors of mice treated with erlotinib after knocking down USP22 were significantly reduced, and the immunohistochemical results showed that tumor cell proliferation decreased and cell apoptosis increased after knocking down USP22. The above suggests that knocking out USP22 in vivo can increase the sensitivity of tumor cells to erlotinib treatment.

[0061] 2.613-MB inhibits the expression of USP22. After H1975 lung cancer cells were treated with different concentrations of 13-MB (0μM, 10μM, 20μM, 40μM, 80μM) for 24 hours, the cells were collected to extract proteins, and the expression of USP22 was detected by Western blot. Figure 6 It can be seen that 13-MB can inhibit the expression of USP22 in lung cancer cells in a dose-dependent manner. The higher the drug concentration, the stronger the effect of inhibiting USP22 expression.

[0062] 2.713-MB inhibits the proliferation, migration and invasion of lung cancer cells and promotes apoptosis of lung cancer cells. H1975 cells were treated with different concentrations (0μM, 20μM, 40μM) of 13-MB. CCK-8 was used to detect the growth and proliferation of H1975 cells. Figure 7As shown in Figure A, 13-MB significantly inhibited the survival rate of H1975 cells in a dose-concentration- and time-dependent manner. The cloning ability of H1975 cells was detected by cloning assay. Figure 7 As shown in Figure B, 13-MB inhibited the colony formation ability of H1975 cells, and the inhibitory effect increased with increasing concentration. The proliferation ability of H1975 cells was detected by EdU cell proliferation assay. Figure 7 As shown in Figure C, 13-MB inhibited the proliferation activity of H1975 cells. As the concentration of 13-MB increased, the inhibitory effect increased. The migration and invasion abilities of H1975 cells were detected by Transwell assay. Figure 7 As shown in Figure D, 13-MB inhibited the migration and invasion of H1975 cells, and the inhibitory effect increased with increasing concentration. The apoptosis level of H1975 cells was detected by flow cytometry. Figure 7 As shown in Figure E, 13-MB promoted the apoptosis of H1975 cells, and the inhibitory effect increased with increasing concentration.

[0063] 2.813-MB enhances the sensitivity of EGFR-TKIs-resistant cell lines to erlotinib. H1975 cells were treated with different concentrations of erlotinib (0μM, 5μM, 10μM, 20μM, 40μM). CCK-8 was used to detect the growth and proliferation of H1975 cells. Figure 8 As shown in Figure A, Erlotinib significantly inhibited the survival rate of H1975 cells in a dose-concentration and time-dependent manner. Figure 8 As shown in Figure B, the CCK-8 method confirmed that 72 hours after the combination of Erlotinib and 13-MB, the sensitivity of H1975 to Erlotinib was enhanced and in a dose-concentration dependent manner.

[0064] 13-MB enhances the therapeutic sensitivity of EGFR-TKIs-resistant cell line H1975 to erlotinib. Experimental group 1 was treated with different concentrations of erlotinib (5μM, 10μM, 20μM, 40μM); experimental group 2 was treated with different concentrations of 13-MB (5μM, 10μM, 20μM, 40μM); experimental group 3 was treated with a fixed concentration (10μM) of 13-MB and different concentrations of erlotinib (5μM, 10μM, 20μM, 40μM); culture medium was used as a blank group; 0.1% DMSO culture medium was used as a control group. After 72 hours of action, 10μl of CCK-8 reagent was added to each well, incubated at 37℃ for 2 hours, and the 96-well plate was taken out and the absorbance value at 450nm was detected using an ELISA reader. Cell proliferation survival rate = (OD value of drug-treated group - OD value of blank group) / (OD value of control group - OD value of blank group) × 100%, inhibition rate = 1 - survival rate. CompuSyn software was used to calculate the combination index CI, and CI ≤ 0.9 was considered to have a potential synergistic effect between the two drugs. The results are shown in Table 1.

[0065] Table 1: Results of determination of lung cancer cell proliferation inhibition rate of erlotinib, 13-MB and their combination

[0066]

[0067] As can be seen from Table 1, when 13-MB is used alone, the inhibition rate of lung cancer cell proliferation increases with the increase of drug concentration. And the inhibition rate of lung cancer cell proliferation in combination with 13-MB and erlotinib is significantly higher than that in the single drug group, which shows that the combination of 13-MB and erlotinib has a strong synergistic effect in inhibiting lung cancer cell proliferation.

[0068] Figure 8 A and B are the survival rates of tumor cells detected by the drug concentrations in Table 1. The CCK-8 method confirmed that after the combination of erlotinib and 13-MB, the sensitivity of the EGFR-TKIs resistant cell line H1975 to erlotinib was enhanced. Next, the inventors used a nude mouse in vivo tumor bearing experiment to evaluate the anti-tumor effect of the combination of 13-MB and erlotinib. The Balb / c Nude mice used in the experiment were 4-6 weeks old female mice. H1975 lung cancer cells (5×10 6 / cells) was made into a 100μl suspension and injected into the back of nude mice. One week after tumor formation, the mice were randomly divided into 4 groups, including the control group, the oral erlotinib group (25mg / kg), the intraperitoneal injection of 13-MB group (8mg / kg), and the erlotinib and 13-MB combination group (erlotinib 25mg / kg combined with 13-MB 8mg / kg). The drugs were administered continuously for 3 weeks. The body weight and tumor size of the mice were measured regularly. The volume of the tumor was calculated as: length × width × width × 0.5. After 3 weeks of administration, the nude mice were killed, the tumors were peeled off, weighed, and photographed. Figure 8 As shown in C and D, the combination of 13-MB and erlotinib can significantly inhibit the tumor volume.

[0069] In summary, the 13-methylberberine of the present invention can significantly inhibit the expression level of USP22 in lung cancer cells, significantly inhibit the proliferation, cloning ability, invasion and migration ability of lung cancer cells, and promote the apoptosis of lung cancer cells. Secondly, 13-methylberberine can also enhance the drug sensitivity of EGFR-TKIs erlotinib. The combination of 13-methylberberine and erlotinib has a strong synergistic effect in the treatment of lung cancer, providing more treatment options for the clinical treatment of lung cancer.

[0070] Obviously, the above embodiments are only examples for clearly explaining the present invention, and are not intended to limit the implementation methods of the present invention. Those skilled in the art may make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.

Claims

1. Use of 13-methylberberine in the preparation of a drug for preventing and / or treating lung cancer, It is characterized in that The molecular formula of the 13-methylberberine is C 21 H 20 ClNO 4 , the chemical structure is as follows:

2. The use according to claim 1, It is characterized in that The 13-methylberberine prevents and / or treats lung cancer by inhibiting the expression of USP22.

3. The use according to claim 1, It is characterized in that The 13-methylberberine prevents and / or treats lung cancer by inhibiting the proliferation, invasion and migration ability of lung cancer cells and promoting apoptosis of lung cancer cells.

4. An application of 13-methylberberine in the preparation of USP22 inhibitors.

5. Use of 13-methylberberine in the preparation of drugs for inhibiting or knocking out USP22.

6. A pharmaceutical composition for preventing and / or treating lung cancer, It is characterized in that The pharmaceutical composition comprises EGFR-TKIs erlotinib and 13-methylberberine, and the molar ratio of the erlotinib to the 13-methylberberine is 0.3-6:

1.

7. The pharmaceutical composition according to claim 6, It is characterized in that The molar ratio of the erlotinib to the 13-methylberberine is 0.5-4:

1.

8. Use of the pharmaceutical composition according to claim 6 or 7 in the preparation of a medicament for preventing and / or treating lung cancer.

9. The use according to claim 8, It is characterized in that The erlotinib and 13-methylberberine in the pharmaceutical composition can be prepared into an oral preparation with a pharmaceutically acceptable carrier or excipient.

10. The use according to claim 9, It is characterized in that The oral preparation is a tablet, a capsule, a granule or an oral liquid.